Author/Authors :
Farhadi، Tayebeh نويسنده Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. , , Karimi، Zeinab نويسنده Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. , , Ghasemi، Younes نويسنده Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran , , Nezafat، Navid نويسنده Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran Nezafat, Navid , Hemmati، Shiva نويسنده , , Erfani، Nasrollah نويسنده Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran ,
Abstract :
Klebsiella pneumoniae is a hospital-acquired pathogen that leads to various infections. Hence, efforts to develop an effective vaccine against that pathogen are well documented. Our interest is the production of the previously designed multi-epitope vaccine construct against the K. pneumoniae in a prokaryotic host. Therefore, a new construct containing the nucleotide sequence of the novel vaccine was successfully expressed in Escherichia coli and then purified by Ni-NTA spin column. The purified recombinant protein can be considered as potential vaccine candidate for wet-laboratory analysis aiming to fight K pneumoniae.
